Smartphone-delivered contingency management is being studied. The economics already make sense.

For a field that has no FDA-approved medication for stimulant use disorder, the most evidence-based intervention has been contingency management for a long time. The barrier has never been efficacy. It’s been delivery.

Two 2026 papers, taken together, reframe the conversation.

The first is a model-based cost-effectiveness analysis published in Addiction. In the modeled cohort with no treatment, 274 overdose deaths and 305 total deaths occurred over one year, and individuals incurred a lifetime healthcare cost of $216,320. Contingency management — even at a conservative $750 incentive cap — was highly cost-effective by standard health economics thresholds. That number, $750, is the one to remember the next time someone calls CM “expensive.”

The second is a qualitative study in JMIR Formative Research that interviewed both patients and clinicians about smartphone-delivered CM. The therapeutic mechanism — small, immediate, biochemically verified rewards for confirmed abstinence — was traditionally a barrier to scale because it required in-person urine testing, in-clinic delivery, and trained staff. Smartphone-based CM solves the geography problem in principle. In practice, the JMIR study surfaced exactly the equity questions you’d expect: device access, data plans, the legitimacy of at-home biochemical verification, and the persistent skepticism among clinicians who have watched too many tech-mediated interventions fail their highest-need patients.

Both findings are important on their own. Together, they’re a quiet warning to the field that the next generation of stimulant treatment is not going to look like a clinic. It’s going to look like a phone, an oral fluid test cassette mailed to a home address, and a clinician who reviews verified abstinence on a dashboard at the end of the week.

What this means for Arizona

Methamphetamine is involved in 67% of fatal overdoses in Maricopa County as of 2024. Stimulant deaths in Arizona have not benefited from the medication-driven decline that fentanyl deaths have nationally — because no medication exists. Smartphone CM is one of the few interventions that could be deployed across a rural-and-urban state in a meaningful way without building new clinics. The settlement-funded organizations applying for a second round of contracts in FY2026 should be looking hard at this.

Why this matters for people in recovery

If you have a stimulant use disorder and have been told there are no medications, that’s still true. What there is is an intervention with a thirty-year evidence base that nobody has been good at making available. Ask your provider about contingency management — and ask whether they’re piloting any smartphone-delivered options. The honest answer is “not yet, but soon” in most parts of the country. That answer is changing this year.

For navigation to stimulant-experienced providers in Arizona, Rize Recovery is in private beta. If you’re in immediate crisis, call 988.